HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
09 03 2023
09 03 2023
Historique:
accepted:
27
10
2022
received:
26
07
2022
revised:
21
09
2022
pmc-release:
28
12
2023
pubmed:
29
12
2022
medline:
11
3
2023
entrez:
28
12
2022
Statut:
ppublish
Résumé
In advanced HER2-positive (HER2+) breast cancer, the new antibody-drug conjugate trastuzumab deruxtecan is more effective compared with trastuzumab emtansine (T-DM1). However, trastuzumab deruxtecan can have considerable toxicities, and the right treatment sequence is unknown. Biomarkers to guide the use of anti-HER2 therapies beyond HER2 status are needed. Here, we evaluated if preestablished levels of ERBB2 mRNA expression according to the HER2DX standardized assay are associated with response and survival following T-DM1. In ERBB2 low, medium, and high groups, the overall response rate was 0%, 29%, and 56%, respectively (P < .001). ERBB2 mRNA was statistically significantly associated with better progression-free survival (P = .002) and overall survival (OS; P = .02). These findings were independent of HER2 immunohistochemistry (IHC) levels, hormone receptor, age, brain metastasis, and line of therapy. The HER2DX risk score (P = .04) and immunoglobulin signature (P = .04) were statistically significantly associated with overall survival since diagnosis. HER2DX provides prognostic and predictive information following T-DM1 in advanced HER2+ breast cancer.
Identifiants
pubmed: 36576009
pii: 6964385
doi: 10.1093/jnci/djac227
pmc: PMC9996199
doi:
Substances chimiques
Ado-Trastuzumab Emtansine
SE2KH7T06F
Maytansine
14083FR882
Antibodies, Monoclonal, Humanized
0
Trastuzumab
P188ANX8CK
Receptor, ErbB-2
EC 2.7.10.1
RNA, Messenger
0
ERBB2 protein, human
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
332-336Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Cancer Res. 2017 May 1;77(9):2213-2221
pubmed: 28249905
N Engl J Med. 2022 Mar 24;386(12):1143-1154
pubmed: 35320644
Cancers (Basel). 2020 Jul 14;12(7):
pubmed: 32674482
N Engl J Med. 2019 Feb 14;380(7):617-628
pubmed: 30516102
EBioMedicine. 2022 Jan;75:103801
pubmed: 34990895
Clin Cancer Res. 2016 Aug 1;22(15):3755-63
pubmed: 26920887
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
Breast Cancer Res. 2014 May 23;16(3):R50
pubmed: 24887458
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
Int J Cancer. 2016 Nov 15;139(10):2336-42
pubmed: 27428671
J Clin Oncol. 2022 Aug 10;40(23):2612-2635
pubmed: 35640077
J Clin Oncol. 2012 Jul 20;30(21):2585-92
pubmed: 22689807
Lancet Oncol. 2014 Jun;15(7):689-99
pubmed: 24793816
J Clin Oncol. 2018 Jul 10;36(20):2105-2122
pubmed: 29846122